IO#12 Iodine Plant

Iofina’s IO#12 plant is commissioned and targets 170–220MT annual iodine output imminently.

What the company is saying

Iofina plc announces that its IO#12 IOsorb® plant, the largest in its portfolio and the first commercial-scale iodine facility in the Permian Basin, has been commissioned and handed to operations. The company highlights that hydrotesting is underway, brine water is flowing, and production is expected to begin and ramp up over the coming weeks. Management frames this as a major operational milestone and emphasizes the partnership with Western Midstream Partners, which is supplying up to 50,000 Bbls/d of produced water. The release stresses the plant’s scale and innovation, positioning the company as a technological leader in iodine extraction. CEO Dr. Tom Becker’s remarks focus on the challenge and achievement of building the facility, while Western Midstream’s CEO Oscar K. Brown underscores the strategic value of the partnership. The company also signals future growth, with two more IOsorb® plants (IO#13 and IO#14) planned for completion in Oklahoma by end of H1 2027, aiming for a 2000MT annual production target. The tone is confident, forward-looking, and operationally detailed, but does not address financial performance or cost data.

What the data suggests

The IO#12 plant is now fully commissioned, with hydrotesting complete and brine water flowing, indicating that the facility is operational and production is imminent. Western Midstream Partners is contracted to supply up to 50,000 barrels per day of produced water, which underpins the plant’s feedstock security. Iofina targets annual production at IO#12 of 170–220 metric tonnes of crystalline iodine, a material increase in capacity. The company currently operates nine IOsorb® plants across three core areas in the United States, and IO#12 is described as the largest to date. Two additional plants (IO#13 and IO#14) are planned for completion by the end of H1 2027, with a long-term goal of reaching 2000MT annual iodine production. The announcement provides no financial figures, revenue, or cost disclosures, so profitability and capital requirements are not assessable. All operational milestones are clearly stated, but the actual production ramp and financial impact remain to be demonstrated.

Analysis

The announcement is upbeat, highlighting the commissioning of IO#12 and imminent production ramp-up, but much of the value proposition is still forward-looking. While hydrotesting and handover to operations are realised milestones, actual iodine production and the targeted annual output (170-220MT) remain projections. The largest capacity and 'first-ever' claims are not substantiated with comparative data. Plans for IO#13 and IO#14, with completion expected by H1 2027, push significant capacity growth and the 2000MT target into the long-term. No financial metrics (revenue, profit, capex) are disclosed, so the sustainability and profitability of this expansion cannot be assessed. The capital intensity is high, with large-scale plant construction and future projects, but immediate earnings impact is not demonstrated. The narrative is moderately inflated by ambitious targets and superlative language without supporting financial or comparative evidence.

Risk flags

• ●There is execution risk in ramping IO#12 from commissioning to full production, as actual output and operational reliability have not yet been demonstrated. Delays or technical issues during ramp-up could defer revenue and impact investor confidence.
• ●The company provides no financial data, cost disclosures, or capital expenditure figures for IO#12 or the planned IO#13 and IO#14 plants, making it impossible to assess profitability, payback, or funding risk. This lack of transparency limits the ability to evaluate the economic viability of the expansion.
• ●Ambitious multi-year targets, such as reaching 2000MT annual iodine production by adding IO#13 and IO#14 by H1 2027, are subject to construction, permitting, and market risks. Any delays or cost overruns could materially affect the company’s growth trajectory and capital requirements.

Bottom line

Iofina’s IO#12 plant is now operational, with brine water flowing and production set to ramp up in the coming weeks, targeting 170–220MT annual iodine output. The partnership with Western Midstream secures up to 50,000 Bbls/d of produced water, supporting feedstock reliability. While the company outlines a clear operational growth path—including two more plants by H1 2027 and a 2000MT production goal—no financial or cost data are disclosed, so the economic impact remains unquantified. The announcement demonstrates operational progress but leaves profitability, capital intensity, and funding sources unaddressed. Investors should focus on actual production volumes and financial results from IO#12 in future updates, as these will determine whether the expansion delivers real shareholder value. The key takeaway is that IO#12 is now commissioned and poised to deliver near-term output, but the investment case will depend on realised production and financial performance.

Announcement summary

(AIM: IOF) Iofina plc has announced the commissioning of its IO#12 IOsorb® plant, which is now undergoing hydrotesting with brine water flowing through the system. Production at IO#12 is expected to begin and ramp up over the coming weeks. IO#12 is the company's largest capacity plant to date and represents the first-ever commercial-scale iodine production facility in the Permian Basin. Western Midstream Partners, LP is supplying up to 50,000 Bbls/d of produced water to the plant. Iofina is targeting an annual production range at IO#12 of between 170-220 metric tonnes of crystalline iodine. Dr. Tom Becker, President and Chief Executive Officer of Iofina plc, confirmed that the plant has been handed over to the operations group. The company is also planning to build its next two IOsorb® plants, IO#13 and IO#14, in the central Oklahoma core area. These two new plants are expected to be completed by the end of H1 2027. Iofina has set a target to reach 2000MT of iodine production. Oscar K. Brown, President and Chief Executive Officer of Western Midstream, commented on the partnership and the value created by combining Western Midstream’s infrastructure and water expertise with Iofina’s iodine recovery technology. Iofina plc is the second largest producer of iodine in North America and operates nine producing IOsorb® plants in three core areas in the United States. Iofina Chemical, a subsidiary, has manufactured halogen specialty chemicals for over 40 years. Western Midstream Partners, LP is a master limited partnership engaged in midstream operations, including the gathering, processing, and transportation of natural gas, condensate, and produced water. The majority of Western Midstream’s cash flows are protected from commodity price volatility through fee-based contracts.

Disagree with this article?